QTTB vs. YS, ASRT, ORMP, IOBT, ANVS, ETON, PRPH, ANIX, GNLX, and CLSD
Should you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include YS Biopharma (YS), Assertio (ASRT), Oramed Pharmaceuticals (ORMP), IO Biotech (IOBT), Annovis Bio (ANVS), Eton Pharmaceuticals (ETON), ProPhase Labs (PRPH), Anixa Biosciences (ANIX), Genelux (GNLX), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical preparations" industry.
Q32 Bio (NASDAQ:QTTB) and YS Biopharma (NASDAQ:YS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
Q32 Bio has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, YS Biopharma has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.
YS Biopharma's return on equity of 0.00% beat Q32 Bio's return on equity.
YS Biopharma has higher revenue and earnings than Q32 Bio.
In the previous week, Q32 Bio's average media sentiment score of 0.00 equaled YS Biopharma'saverage media sentiment score.
Q32 Bio received 1 more outperform votes than YS Biopharma when rated by MarketBeat users.
Q32 Bio presently has a consensus target price of $47.50, suggesting a potential upside of 56.46%. YS Biopharma has a consensus target price of $5.25, suggesting a potential upside of 461.26%. Given YS Biopharma's higher probable upside, analysts plainly believe YS Biopharma is more favorable than Q32 Bio.
31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 52.6% of YS Biopharma shares are held by institutional investors. 16.1% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
YS Biopharma beats Q32 Bio on 7 of the 11 factors compared between the two stocks.
Get Q32 Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
